# AZTR catalysts: Azitra, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aztr/catalysts

> Azitra, Inc. (AZTR) has no upcoming catalysts in this calendar. The latest recorded is the Azitra, Inc. earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for AZTR?

Azitra, Inc. (AZTR) has no upcoming catalysts in this calendar. The latest recorded is the Azitra, Inc. earnings report, November 12, 2026. Press release filed with the SEC (EX-99): "BRANFORD, Conn. - November 12, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended September 30, 2026, and provided a business update." [Calendar and source filings](https://sec-api.dev/companies/aztr/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001701478-26-000051, https://www.sec.gov/Archives/edgar/data/1701478/000170147826000051/aztrpressrelease9302026-ex.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/aztr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Azitra, Inc. |
| Ticker | AZTR (NYSE) |
| SEC CIK | 1701478 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/aztr |

## Cash runway

Cash $3.8M as of 2026-09-30; quarterly burn $2.9M; about 3.9 months of runway at that rate (XBRL company facts, accession 0001701478-26-000049).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 27, 2023 | [ATR-12 trial start](https://sec-api.dev/pdufa/atr-12) | AZTR |  | completed | "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase 1b clinical trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000028/aztr-20260331.htm)) |
| Dec 2023 | [ATR-12 trial start](https://sec-api.dev/pdufa/atr-12) | AZTR |  | completed | "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000049/aztr-20260930.htm)) |
| Aug 2024 | [ATR-12 trial start](https://sec-api.dev/pdufa/atr-12) | AZTR |  | completed | "In August 2024, we initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients to assess multiple safety, tolerability, and efficacy endpoints." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/ex99-1.htm)) |
| November 12, 2024 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "Inc. Announces Q3 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000149315224044930/ex99-1.htm)) |
| February 24, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "Inc. Announces Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/ex99-1.htm)) |
| May 13, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "Conn. - May 13, 2025 — Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/ex99-1.htm)) |
| Aug 2025 | [ATR-04 trial start](https://sec-api.dev/pdufa/atr-04) | AZTR |  | completed | "•Dosed first patient in Phase 1/2 trial for ATR-04 program targeting oncology patients with EGFRi-associated rash in August 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/aztrpressrelease09302025-e.htm)) |
| August 11, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - August 11, 2025 — Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/aztrpressrelease06302025-e.htm)) |
| late 2025 | [ATR-12 topline data readout](https://sec-api.dev/pdufa/atr-12) | AZTR |  | scheduled | "ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we expect to provide initial safety data from our Phase 1b trial in the first half of 2025 with topline results expected by year-end 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/ex99-1.htm)) |
| November 12, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - November 12, 2025 — Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/aztrpressrelease09302025-e.htm)) |
| Q1 2026 | [ATR-12 topline data readout](https://sec-api.dev/pdufa/atr-12) | AZTR |  | scheduled | "We reported initial clinical safety results in the first half of 2025, and expect to report topline data in the first quarter of 2026." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1701478/000149315225027067/forms-1.htm)) |
| February 27, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - February 27, 2026 — Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/aztrpressrelease12312025-e.htm)) |
| mid-2026 | [ATR-04 topline data readout](https://sec-api.dev/pdufa/atr-04) | AZTR |  | scheduled | "•Topline data from first cohort of Phase 1/2 trial expected around mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/aztrpressrelease12312025-e.htm)) |
| May 13, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - May 13, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztrpressrelease3312026-ex.htm)) |
| 2H 2026 | [Azitra, Inc. topline data readout](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | scheduled | "•Topline data from the Phase 1b trial is anticipated H2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztrpressrelease3312026-ex.htm)) |
| Q3 2026 | [ATR-04 interim data readout](https://sec-api.dev/pdufa/atr-04) | AZTR |  | scheduled | "We dosed the first patient in the Phase 1/2 clinical trial in the third quarter of 2025 and plan to announce initial data from Cohort 1 of the trail around Q3 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000028/aztr-20260331.htm)) |
| August 12, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - August 12, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/aztrpressrelease6302026-ex.htm)) |
| Q4 2026 | [ATR-04 topline data readout](https://sec-api.dev/pdufa/atr-04) | AZTR |  | scheduled | "We are encouraged by the potential to reach additional patient populations and look forward to reporting topline data from Cohort 1, which we anticipate in the fourth quarter of 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000051/aztrpressrelease9302026-ex.htm)) |
| Q4 2026 | [ATR-04 interim data readout](https://sec-api.dev/pdufa/atr-04) | AZTR |  | scheduled | "We dosed the first patient in the Phase 1/2 clinical trial in the third quarter of 2025 and plan to announce initial data from Cohort 1 of the trial around Q4 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000037/aztr-20260630.htm)) |
| November 12, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - November 12, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended September 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000051/aztrpressrelease9302026-ex.htm)) |

## Drugs

- [ATR-04](https://sec-api.dev/pdufa/atr-04): 
- [ATR-12](https://sec-api.dev/pdufa/atr-12): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aztr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AZTR catalysts: Azitra, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aztr/catalysts

```bibtex
@misc{secapidev_companies_aztr_catalysts_20261116,
  title        = {AZTR catalysts: Azitra, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aztr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aztr_catalysts_20261116","title":"AZTR catalysts: Azitra, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aztr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
